Prevention Trial to Achieve Cardiovascular Targets
| Status: | Recruiting |
|---|---|
| Conditions: | High Blood Pressure (Hypertension), High Cholesterol, Obesity Weight Loss, Peripheral Vascular Disease, Cardiology, Endocrine, Diabetes |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Endocrinology |
| Healthy: | No |
| Age Range: | 21 - 99 |
| Updated: | 4/21/2016 |
| Start Date: | June 2012 |
| End Date: | June 2017 |
| Contact: | Ramsha Jabbar, B.A. |
| Email: | Ramsha.Jabbar@nyumc.org |
| Phone: | 646-501-2666 |
Investigation of Motivational Interviewing and Prevention Consults to Achieve Cardiovascular Targets
The objective of IMPACT (Investigation of Motivational Interviewing and Prevention Consults
to Achieve Cardiovascular Targets) is to determine the best management strategy for patients
undergoing cardiovascular intervention. IMPACT is a prospective randomized trial that will
enroll 400 patients post-cardiovascular intervention. The study will compare different
cardiovascular prevention strategies: (1) usual care, (2) cardiovascular prevention consult,
and (3) cardiovascular prevention consult with a behavioral intervention program over a
6-month period. The trial hypothesis is that for patients undergoing a cardiovascular
intervention, a prevention consult and behavioral intervention is superior to usual care in
reducing cardiovascular risk. The primary endpoint will be non-HDL cholesterol. Secondary
endpoints include other lipid values, metabolic risk, smoking cessation, physical activity,
nutritional status, medication adherence and quality of life. IMPACT is scheduled to begin
enrollment in the June of 2012.
to Achieve Cardiovascular Targets) is to determine the best management strategy for patients
undergoing cardiovascular intervention. IMPACT is a prospective randomized trial that will
enroll 400 patients post-cardiovascular intervention. The study will compare different
cardiovascular prevention strategies: (1) usual care, (2) cardiovascular prevention consult,
and (3) cardiovascular prevention consult with a behavioral intervention program over a
6-month period. The trial hypothesis is that for patients undergoing a cardiovascular
intervention, a prevention consult and behavioral intervention is superior to usual care in
reducing cardiovascular risk. The primary endpoint will be non-HDL cholesterol. Secondary
endpoints include other lipid values, metabolic risk, smoking cessation, physical activity,
nutritional status, medication adherence and quality of life. IMPACT is scheduled to begin
enrollment in the June of 2012.
SPECIFIC AIMS
Primary aim:
The primary aim is that a targeted Cardiovascular Prevention consult will reduce non-HDL
cholesterol compared to usual care at 6 months post-intervention.
Secondary aim:
The secondary aim is that a targeted Cardiovascular Prevention consult plus a behavioral
intervention will reduce non-HDL cholesterol compared to usual care at 6 months
post-intervention.
Primary aim:
The primary aim is that a targeted Cardiovascular Prevention consult will reduce non-HDL
cholesterol compared to usual care at 6 months post-intervention.
Secondary aim:
The secondary aim is that a targeted Cardiovascular Prevention consult plus a behavioral
intervention will reduce non-HDL cholesterol compared to usual care at 6 months
post-intervention.
Inclusion Criteria:
- at least 21 years of age or older
- Subjects scheduled to undergo a percutaneous coronary or peripheral vascular
intervention
- Patients must have the ability to understand and the willingness to sign a written
informed consent document
Exclusion Criteria:
- Life expectancy less than 1-year
- Inability to walk
We found this trial at
1
site
550 1st Ave
New York, New York 10016
New York, New York 10016
(212) 263-7300
Phone: 646-501-2666
New York University Langone Medical Center NYU NYU Langone Medical Center, a world-class, patient-centered, integrated,...
Click here to add this to my saved trials
